Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
ABBVIE LIMITED,Venetoclax (w widened access to azacitidine or low dose cytarabine),"Acute myeloid leukaemia, newly diagnosed, ineligible for intensive induction chemotherapy",Venetoclax (w widened access to azacitidine or low dose cytarabine) (Venclexta),Community and Hospital,Oncology Agents and Immunosuppressants
